### 一、产品名称

ResearchGradeBlisibimod，简称XPJ科研级贝利西单抗，精品蛋白抗体试剂盒

### 二、产品简介

Blisibimod (A623) 是一种高效且选择性的四价B细胞激活因子 (BAFF) 抑制剂，专为系统性红斑狼疮 (SLE) 的研究而设计。该产品在生物医药领域为科研工作者提供了全方位的支持。

### 三、产品详情

**名称**: ResearchGradeBlisibimod - XPJ科研级贝利西单抗，体内中和抗体，活性抗体

**货号**: DHJ85305

**表达系统**: 哺乳动物细胞

**种属反应性**: 人类

**宿主**: 人类

**同种型**: Fusion-[peptide16-mer-peptide19-mer]2-IGHG1Fc (Fragment constant)

**靶标**: BAFF, ZTNF4, BLYS, 肿瘤坏死因子配体超家族成员13B, 树突状细胞衍生的TNF-样分子, TALL-1, TNF及APOL相关白细胞表达配体1, BLyS, B淋巴细胞刺激因子, TNFSF13B, CD257, TNFSF20, TALL1, B细胞激活因子

**浓度**: 0.5 mg/ml

**内毒素水平**: 请联系实验室获取相关信息

**纯度**: 通过SDS-PAGE鉴定达到95%

**纯化方式**: 从细胞培养上清液中通过Protein A/G纯化

**Accession号**: Q9Y275

**克隆号**: Blisibimod

**应用**: 适用于生物医学研究

**状态**: 液体

**保存溶液**: 0.01M PBS, pH 7.4

**稳定性和存储**:

• 使用手动解冻冰箱，避免重复冻融
• 短期（1-2周）储存于4°C
• 长期储存于-20°C可达12个月
• 长期储存于-80°C

**别名**: A-623

### 四、参考文献

有关Blisibimod治疗系统性红斑狼疮的研究，请参见以下文献:

• “Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser” PMID: 27051973
• “Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date” PMID: 28331294
• “An narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)” PMID: 37755547
• “The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity” PMID: 23684423
• “Advances in natural products and antibody drugs for SLE: new therapeutic ideas” PMID: 37492083
• “Emerging B-Cell Therapies in Systemic Lupus Erythematosus” PMID: 33488082
• “Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial” PMID: 29563108
• “Treatment of systemic lupus erythematosus patients with the BAFF antagonist 'peptibody' blisibimod (AMG623/A-623): results from randomized, double-blind phase 1a and phase 1b trials” PMID: 26290435
• “A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study” PMID: 24748629
• “Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus” PMID: 24521424

如需了解更多详细信息，请咨询XPJ品牌中国授权总代理——武汉佰乐博生物技术有限公司。作为XPJ在亚洲的授权总代理，我们提供近3万种蛋白、抗体等核心生命科学试剂，致力于为生命科学科研工作者提供专业、全面、可靠的试剂产品。

**联系电话**: 027-65279366 / 18108604356